Aspire Biopharma (ASBP) Stock Price, News & Analysis

Company Overview

Aspire Biopharma, Inc. is a clinical-stage biopharmaceutical company developing drug-delivery products based on proprietary oral thin-film technology. Its platform is designed to deliver medication through the mouth without requiring water or conventional swallowing, with the goal of enabling rapid absorption and improving ease of use.

The company’s lead development program is an orally administered aspirin product intended for potential use in acute cardiovascular situations, where rapid delivery may be important. Aspire Biopharma is also evaluating additional applications of its delivery platform for other pharmaceutical compounds and therapeutic areas.

The company’s products remain under development and require regulatory review and approval before they can be marketed. Aspire Biopharma became a publicly traded company following a business combination with PowerUp Acquisition Corp. in 2024.

Key Stats

• Today's Range: $8.33 to $8.81
• 50-Day Range: $5.61 to $9.25
• 52-Week Range: $3.31 to $562.92
• Volume: 16,533 shs
• Average Volume: 32,689 shs
• Market Capitalization: $12.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Aspire Biopharma Stock Analysis - MarketRank™

Aspire Biopharma scored higher than 9% of companies evaluated by MarketBeat, and ranked 456th out of 477 stocks in the consumer discretionary sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Aspire Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Aspire Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aspire Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aspire Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.62% of the float of Aspire Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Aspire Biopharma has a short interest ratio ("days to cover") of 0.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aspire Biopharma has recently decreased by 19.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aspire Biopharma does not currently pay a dividend.

Dividend Growth

Aspire Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Aspire Biopharma this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Aspire Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aspire Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.80% of the stock of Aspire Biopharma is held by insiders.

Percentage Held by Institutions

19.17% of the stock of Aspire Biopharma is held by institutions.

Company Calendar

• Last Earnings: 11/14/2025
• Today: 10/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Discretionary
• Industry: Automobile Components
• Sub-Industry: Automotive Parts & Equipment
• Current Symbol: NASDAQ:ASBP
• Previous Symbol: NASDAQ:PWUP
• CIK: 1847345
• Web: aspirebiolabs.com
• Phone: (561) 704-8527
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($69.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.48 million
• Net Margins: -11,362.21%
• Pretax Margin: -11,361.18%
• Return on Equity: N/A
• Return on Assets: -177.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.82

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,229.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($54.19) per share
• Price / Book: -0.16

Miscellaneous

• Outstanding Shares: 1,400,000
• Free Float: 1,322,000
• Market Cap: $12.29 million
• Optionable: N/A
• Beta: 0.17